CD4+ and CD8+ T-lymphocyte scores cannot reliably predict progression in patients with benign prostatic hyperplasia

BJU International

Volumn 108, Issue 2 B, 2011, Pages

  Lamb, Alastair D ^a   Qadan, Motaz ^a   Roberts, Simon ^a   Timlin, Hannah ^a   Vowler, Sarah L ^a   Campbell, Fiona M ^d   Grigor, Ken ^b   Bartlett, John M S ^c   McNeill, S Alan ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b Endocrine Cancer Group   (United Kingdom)

^c WESTERN GENERAL HOSPITAL   (United Kingdom)

^d Bioinformatics Core   (United Kingdom)

Author keywords

benign prostatic hyperplasia; CD4; CD8; inflammation; progression; T lymphocyte

Indexed keywords

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DENSITY; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HUMAN CELL; HUMAN TISSUE; LOWER URINARY TRACT SYMPTOM; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; RELIABILITY; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; TRANSRECTAL ULTRASONOGRAPHY;

AGED; AGED, 80 AND OVER; CD4 LYMPHOCYTE COUNT; CD8-POSITIVE T-LYMPHOCYTES; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATIC HYPERPLASIA; URINATION DISORDERS;

EID: 79960107458     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09787.x     Document Type: Article

References (22)

1. Kramer G, Marberger M,. Could inflammation be a key component in the progression of benign prostatic hyperplasia? Curr Opin Urol 2006; 16: 25-9 (Pubitemid 43041217)
2. Kohnen PW, Drach GW,. Patterns of inflammation in prostatic hyperplasia: a histologic and bacteriologic study. J Urol 1979; 121: 755-60 (Pubitemid 9205780)
3. Kramer G, Mitteregger D, Marberger M,. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol 2007; 51: 1202-16 (Pubitemid 46436310)
4. Kramer G, Steiner GE, Handisurya A, et al,. Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation. Prostate 2002; 52: 43-58 (Pubitemid 34553191)
5. Roehrborn CG,. The MTOPS Research Group. The Impact of acute or chronic inflammation in baseline biopsy on the risk of progression in the MTOPS study. Eur Urol Suppl 2005; 4: 5. Abstract No 10
6. Rohrmann S, De Marzo AM, Smit E, Giovannucci E, Platz EA,. Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III). Prostate 2005; 62: 27-33 (Pubitemid 39614290)
7. Royuela M, Ricote M, Parsons MS, Garcia-Tunon I, Paniagua R, de Miguel MP,. Immunohistochemical analysis of the IL-6 family of cytokines and their receptors in benign, hyperplasic, and malignant human prostate. J Pathol 2004; 202: 41-9 (Pubitemid 38072844)
8. Castro P, Xia C, Gomez L, Lamb DJ, Ittmann M,. Interleukin-8 expression is increased in senescent prostatic epithelial cells and promotes the development of benign prostatic hyperplasia. Prostate 2004; 60: 153-9 (Pubitemid 38758580)
9. Steiner GE, Stix U, Handisurya A, et al,. Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue. Lab Invest 2003; 83: 1131-46 (Pubitemid 37013048)
10. Difuccia B, Keith I, Teunissen B, Moon T,. Diagnosis of prostatic inflammation: efficacy of needle biopsies versus tissue blocks. Urology 2005; 65: 445-8 (Pubitemid 40385985)
11. McConnell JD, Roehrborn CG, Bautista OM, et al,. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-98 (Pubitemid 37542987)
12. Bromwich EJ, McArdle PA, Canna K, et al,. The relationship between T-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer. Br J Cancer 2003; 89: 1906-8 (Pubitemid 37533268)
13. Anderson JD, Dunnill MS,. Observations on the estimation of the quantity of emphysema in the lungs by the point-sampling method. Thorax 1965; 20: 462-6
14. Arkin CF, Wachtel MS,. How many patients are necessary to assess test performance? JAMA 1990; 263: 275-8 (Pubitemid 20025984)
15. Nickel J,. Inflammation and benign prostatic hyperplasia. Urol Clin North Am 2008; 35: 109-15 (Pubitemid 350166524)
16. Andriole GBD, Brawley O, Gomella L, et al,. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 2004; 172: 1314-7 (Pubitemid 39249705)
17. Vykhovanets EV, Resnick MI, Marengo SR,. The healthy rat prostate contains high levels of natural killer-like cells and unique subsets of CD4+ helper-inducer T cells: implications for prostatitis. J Urol 2005; 173: 1004-10 (Pubitemid 40239385)
18. Wang L, Yang JR, Yang LY, Liu ZT,. Chronic inflammation in benign prostatic hyperplasia: implications for therapy. Med Hypotheses 2008; 70: 1021-3 (Pubitemid 351400693)
19. Ozdemir I, Bozkurt O, Demir O, Aslan G, Esen AA,. Combination therapy with doxazosin and tenoxicam for the management of lower urinary tract symptoms. Urology 2009; 74: 431-5
20. McArdle PA, Canna K, McMillan DC, McNicol AM, Campbell R, Underwood MA,. The relationship between T-lymphocyte subset infiltration and survival in patients with prostate cancer. Br J Cancer 2004; 91: 541-3 (Pubitemid 39093576)
21. Murri AM, Hilmy M, Bell J, et al,. The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic and macrophage infiltration, microvessel density and survival in patients with primary operable breast cancer. Br J Cancer 2008; 99: 1013-9
22. Robert G, Descazeaud A, Nicolaiew N, et al,. Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis. Prostate 2009; 69: 1774-80